Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.

AIDS research and human retroviruses - 1 Feb 2013

Hicks Charles, Clay Patrick, Redfield Robert, Lalezari Jay, Liporace Ralph, Schneider Stefan, Sension Michael, McRae MaryPeace, Laurent Jean-Pierre

Abstract excerpt

Treatment of HIV infection with conventional antiretroviral therapy (ART) is a lifelong challenge with significant long-term risks of adverse events and treatment failure-induced HIV resistance being major concerns. One potential alternative to standard treatment is the use of viral decay acceler...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to HIV Infections

Share to Nucleosides

Share to RNA, Viral

Share to Treatment Outcome

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 22738014
DOI: 10.1089/AID.2012.0093
PMCID: PMC3552433

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22738014-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.PMID 22738014Read ↗

Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461.Semantic proximity Read ↗

KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.Semantic proximity Read ↗

Mutations based on viral decay acceleration in the HIV-1 genomes of a clinical population treated with the mutagenic nucleoside KP1461Semantic proximity Read ↗

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.Semantic proximity Read ↗

Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.Semantic proximity Read ↗

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.Semantic proximity Read ↗

Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.Semantic proximity Read ↗

Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy.Semantic proximity Read ↗

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants.Semantic proximity Read ↗

Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients.Semantic proximity Read ↗

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.Semantic proximity Read ↗

Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.